Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)

International Immunology

Volumn 19, Issue 3, 2007, Pages 337-343

  Polanczyk, Magdalena J ^a,b,c   Hopke, Corwyn ^a   Vandenbark, Arthur A ^a,b   Offner, Halina ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; PROGRAMMED DEATH 1 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG MECHANISM; ESTROGEN ACTIVITY; FEMALE; HORMONE SENSITIVITY; IMMUNIZATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; WILD TYPE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CELLS, CULTURED; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLYCOPROTEINS; IMMUNIZATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; RECEPTORS, ESTROGEN; T-LYMPHOCYTES, REGULATORY;

EID: 33847345997     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl151     Document Type: Article

References (30)

1. Whitacre, C. C., Reingold, S. C. and O'Looney, P. A. 1999. A gender gap in autoimmunity. Science 283:1277.
2. Voskuhl, R. R., Pitchekian-Halabi, H., MacKenie-Graham, A., McFarland, H. F. and Raine, C. S. 1996. Gender differences in autoimmune demyelination in the mouse: Implications for multiple sclerosis. Ann. Neurol. 39:724.
3. Reddy, J., Waldner, H., Zhang, X. et al. 2005. Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 175:5591.
4. Cohen-Solal, J. F., Jeganathan, V., Grimaldi, C. M., Peeva, E. and Diamond, B. 2006. Sex hormones and SLE: Influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol. 305:67.
5. Hiltunen, M., Iivonen, S. and Soininen, H. 2006. Aromatase enzyme and Alzheimer's disease. Minerva Endocrinol. 31:61.
6. Lambert, K. C., Curran, E. M., Judy, B. M., Milligan, G. N., Lubahn, D. B. and Estes, D. M. 2005. Estrogen receptor alpha (ERalpha) deficiency in macrophages results in increased stimulation of CD4+ T cells while 17beta-estradiol acts through ERalpha to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation. J. Immunol. 175:5716.
7. Ambrogini, E., Toraldo, G. and Marcocci, C. 2005. Post-menopausal osteoporosis: Is it an autoimmune disease? J. Endocrinol. Investig. 28:43.
8. Bebo, B. F. Jr, Zelinka-Vincent, E., Adamus, G., Amundson, D., Vandenbark, A. A. and Offner, H. 1998. Gonadal hormones influence the immune response to PLP 139-151 and the clinical course of relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 84:122.
9. Bebo, B. F. Jr, Schuster, J. C., Vandenbark, A. A. and Offner, H. 1998. Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. J. Neurosci. Res. 52:420.
10. Ito, A., Bebo, B. F., Matejuk, A. et al. 2001. Estrogen treatment down-regulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J. Immunol. 167:542.
11. Bebo, B. F., Fyfe-Johnson, A., Adlard, K., Beam, A. G., Vandenbark, A. A. and Offner, H. 2001. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol. 166:2080.
12. Polanczyk, M. J., Carson, B. D., Subramanian, S. et al. 2004. Cutting edge: Estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J. Immunol. 173:2227.
13. Polanczyk, M. J., Hopke, C., Huan, J., Vandenbark, A. A. and Offner, H. 2005. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J. Neuroimmunol. 170:85.
14. Londei, M. 2005. Role of regulatory T cells in experimental arthritis and implications for clinical use. Arthritis Res. Ther. 7:118.
15. Verginis, P., Li, H. S. and Carayanniotis, G. 2005. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J. Immunol. 174:7433.
16. Saito, S., Sasaki, Y. and Sakai, M. 2005. CD4(+)CD25high regulatory T cells in human pregnancy. J. Reprod. Immunol. 65:111.
17. Gartner, D., Hoff, H., Gimsa, U., Burmester, G. R. and Brunner-Weinzierl, M. C. 2006. CD25 regulatory T cells determine secondary but not primary remission in EAE: Impact on long-term disease progression. J. Neuroimmunol. 172:73.
18. Venken, K., Hellings, N., Hensen, K. et al. 2006. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FoxP3 expression. J. Neurosci. Res. 83:1432.
19. Haas, J., Hug, A., Viehover, A. et al. 2005. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35:3343.
20. Vandenbark, A. A. 2005. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr. Drug Targets Inflamm. Allergy 4:217.
21. Huan, J., Culbertson, N., Spencer, L. et al. 2005. Decreased FoxP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81:45.
22. Kroner, A., Mehling, M., Hemmer, B. et al. 2005. PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann. Neurol. 58:50.
23. Raimondi, G., Shufesky, W. J., Tokita, D., Morelli, A. E. and Thomson, A. W. 2006. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J. Immunol. 176:2808.
24. Gavin, M. A., Clarke, S. R., Negrou, E., Gallegos, A. and Rudensky, A. 2002. Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo. Nat. Immunol. 3:33.
25. Polanczyk, M. J., Hopke, C., Vandenbark, A. A. and Offner, H. 2006. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J. Neurosci. Res. 84:370.
26. Polanczyk, M., Zamora, A., Subramanian, S. et al. 2003. The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am. J. Pathol. 163:1599.
27. Kisielow, P. and von Boehmer, H. 1995. Development and selection of T cells: Facts and puzzles. Adv. Immunol. 58:87.
28. Kisielow, P., Bluthmann, H., Staerz, U. D., Steinmetz, M. and von Boehmer, H. 1988. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 333: 742.
29. Viglietta, V., Baecher-Allan, C., Weiner, H. L. and Hafler, D. A. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971.
30. Offner, H. 2004. Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: Therapeutic implications for multiple sclerosis. J. Neurosci. Res. 78:603.